| Drug Name |
Conjugated estrogens |
| Drug ID |
BADD_D00528 |
| Description |
The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.[L5605, T475]
The conjugated estrogen product contains a mix of estrogen from which about 50% is represented by estrone sulfate followed by 25% of equilin sulfate, 15% of 17-alpha-dehydroequilenin sulfate, 3% of equilenin sulfate, 5% of 17-alpha and 17-beta-dihydroequilenin sulfate, 2% of 17-alpha-estradiolsulfate and 3% of 17-beta-estradiolsulfate. It also presents a large number of unidentified molecules with weak estrogenic activity as well as non-human molecules when it is obtained from pregnant mares urine.[T475]
The conjugated estrogen mixture was approved for marketing in US in 1942 based on the efficacy against certain conditions. However, until 1986 official clinical trials were performed and this product was determined to be effective for the treatment of osteoporosis.[T484] The currently approved product of conjugated estrogens was developed by Wyeth Ayerst and FDA approved in 2003.[L5608] |
| Indications and Usage |
The conjugated estrogens are indicated for several different conditions including:
- Treatment of moderate to severe vasomotor symptoms due to menopause.
- Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.
- Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure.
- Palliative treatment of breast cancer in appropriately selected patients with metastatic disease.
- Palliative treatment of androgen-dependent carcinoma of the prostate.
- Preventive therapy of postmenopausal osteoporosis.[A38238] |
| Marketing Status |
approved |
| ATC Code |
G03CA57 |
| DrugBank ID |
DB00286
|
| KEGG ID |
D04070
|
| MeSH ID |
D004966
|
| PubChem ID |
45357473
|
| TTD Drug ID |
D0T0LU
|
| NDC Product Code |
42816-1100; 42816-1101; 70203-101; 0046-0749; 42816-0101; 42816-1103; 0046-0872; 42816-1104; 42816-1102 |
| UNII |
Not Available
|
| Synonyms |
Estrogens, Conjugated (USP) | Estrogenic Hormones, Conjugated | Conjugated Estrogenic Hormones | Estrogens, Conjugated | Estrogenic Substances, Conjugated | Conjugated Estrogenic Substances | Conjugated Estrogens | Conjugated Estrogen | Estrogen, Conjugated | Congest | Conjugated Equine Estrogens | Equine Estrogens, Conjugated | Conjugated Equine Estrogen | Equine Estrogen, Conjugated | Estrogen, Conjugated Equine | Dagynil | Oestrofeminal | Oestro-Feminal | Oestro Feminal | Estro-Feminal | Estro Feminal | Premarin | Climopax | Climarest | Presomen | Progens | Progen | Transannon | Femavit | Carentil | Prelestrin |
